טוען...
Galeterone for the treatment of advanced prostate cancer: the evidence to date
Major advances have been achieved recently in the treatment of metastatic castration-resistant prostate cancer, resulting in significant improvements in quality of life and survival with the use of several new agents, including the next-generation androgen receptor (AR)-targeted drugs abiraterone an...
שמור ב:
| הוצא לאור ב: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Dove Medical Press
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4956059/ https://ncbi.nlm.nih.gov/pubmed/27486306 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S93941 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|